Alexion Pharmaceuticals Inc., of Cheshire, Conn., said researchers presented data from an integrated analysis of survival from two open-label, phase II studies of asfotase alfa in pediatric patients (ages ≤ 5 years at enrollment) with hypophosphatasia (HPP) compared with data from a retrospective natural history study of untreated historical control patients matched for age and disease severity.